Experimental breast cancer vaccine proves safe in phase 1 clinical trials
- Breast cancer is currently the most frequently diagnosed cancerTrusted Source in the United States, and globally it is the world’s most prevalent cancer.Trusted Source
- According to new phase 1 clinical trial data, a new plasmid DNA-based vaccine that is able to target a receptor in breast cancer appears safe.
- The non-randomized study showed an increased immune response after vaccination in people with advanced-stage ERBB2-positive breast cancer.
According to the World Health OrganizationTrusted Source, 2.3 million women were diagnosed with breast cancer in 2020, and there were over 7.8 million women alive who had been diagnosed with breast cancer in the previous 5 years.
Being female is the biggest risk factor for breast cancer, but around 1% of breast cancers do occur in men. The treatment of breast cancer follows the same principles for both sexes.
Speaking to Medical News Today Dr. Kotryna Temcinaite, senior research communications manager at Breast Cancer Now explained:
“Breast cancer is not a single disease, which makes it more difficult to treat. There are many types of breast cancer and treatments that work well for some people, may not work as well for others. That’s why we need to undertake further research into the disease, develop [k]inder and smarter treatments.”
Now, new research led by Dr. Mary (Nora) L. Disis, at the University of Washington Medicine Cancer Vaccine Institute on an experimental vaccine against breast cancer has shown it generates a strong immune response to ERBB2—formerly called HER2—a key tumor protein.
The study is published in the journal JAMA OncologyTrusted Source
